Volume 23, Number 3—March 2017
Synopsis
Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007–2014
Robert Whittaker
, Assimoula Economopoulou1, Joana Gomes Dias, Elizabeth Bancroft2, Miriam Ramliden3, Lucia Pastore Celentano, and European Centre for Disease Prevention and Control Country Experts for Invasive Haemophilus influenzae Disease
, Assimoula Economopoulou1, Joana Gomes Dias, Elizabeth Bancroft2, Miriam Ramliden3, Lucia Pastore Celentano, and European Centre for Disease Prevention and Control Country Experts for Invasive Haemophilus influenzae Disease
Table 2
Mean annual notification rate per 100,000 population and number of cases of invasive Haemophilus influenzae disease by serotype and patient age group, in 12 European countries, 2007–2014*
| Variable |
Mean annual notification rate/100,000 population, by serotype (no. cases)† |
Mean overall annual notification rate (no. cases) |
|||||||||
| Hia |
Hib |
Hic |
Hid |
Hie |
Hif |
NTHi |
Non-b |
Total with data |
Unknown |
||
| Age group | |||||||||||
| <1 y | 0.05 (9) | 0.65 (118) | 0 | 0 | 0.06 (11) | 0.30 (54) | 3.17 (578) | 0.005 (1) | 4.24 (771) | 0.64 (117) | 4.90 (888) |
| <1 mo‡ | 0.07 (1) | 0.29 (4) | 0 | 0 | 0 (0) | 0.22 (3) | 19.37 (263) | 0 | 19.96 (271) | 3.46 (47) | 23.42 (318) |
| 1–5 mo‡ | 0.01 (1) | 0.65 (44) | 0 | 0 | 0.06 (4) | 0.22 (15) | 1.75 (119) | 0.01 (1) | 2.71 (184) | 0.52 (35) | 3.23 (219) |
| 6–11 mo‡ | 0.09 (7) | 0.74 (60) | 0 | 0 | 0.09 (7) | 0.33 (27) | 1.44 (117) | 0 | 2.68 (218) | 0.32 (26) | 3.00 (244) |
| 1–4 y | 0.006 (4) | 0.18 (132) | 0.001 (1) | 0.003 (2) | 0.01 (8) | 0.07 (52) | 0.51 (369) | 0.006 (4) | 0.79 (572) | 0.11 (80) | 0.90 (652) |
| 5–19 y | <0.001 (1) | 0.02 (54) | <0.001 (1) | 0 | 0.003 (9) | 0.01 (26) | 0.10 (277) | <0.001 (1) | 0.14 (369) | 0.03 (93) | 0.17 (462) |
| 20–39 y | <0.001 (1) | 0.02 (71) | 0 | <0.001 (1) | 0.003 (12) | 0.01 (50) | 0.15 (648) | <0.001 (2) | 0.18 (785) | 0.05 (207) | 0.22 (992) |
| 40–59 y | <0.001 (4) | 0.04 (189) | 0 | <0.001 (1) | 0.009 (41) | 0.03 (153) | 0.21 (980) | <0.001 (1) | 0.30 (1,369) | 0.08 (354) | 0.37 (1,723) |
| >60 y |
0.001 (4) |
0.06 (247) |
0 |
<0.001 (6) |
0.04 (158) |
0.13 (493) |
1.03 (4,001) |
<0.001 (6) |
1.27 (4,915) |
0.26 (992) |
1.53 (5,907) |
| Overall notification rate (no. cases)§ |
0.001 (23) |
0.05 (811) |
<0.001 (2) |
<0.001 (10) |
0.01 (239) |
0.05 (828) |
0.42 (6,853) |
<0.001 (15) |
0.53 (8,781) |
0.11 (1,843) |
0.64 (10,624) |
| Median age, y§ |
2 |
43 |
3 |
69 |
66 |
64 |
65 |
32 |
64 |
62 |
63 |
| IQR, y§ |
0–55 |
3–63 |
1–5 |
33–76 |
53–78 |
45–75 |
35–79 |
2–83 |
33–78 |
37–76 |
34–77 |
| *The study was conducted in Belgium, Cyprus, the Czech Republic, Denmark, Finland, Ireland, Italy, the Netherlands, Norway, Slovenia, Spain, and the United Kingdom. Data are for a total of 10,624 cases. Hia, H. influenzae serotype a; Hib, serotype b; Hic, serotype c; Hid, serotype d; Hie, serotype e; Hif, serotype f; NTHi, nontypeable H. influenzae; non-b, cases reported as a non-b H. influenzae strain (It was not known whether these cases were encapsulated); IQR, interquartile range. †Values are mean annual notification rate/100,000 population (no. cases), except as indicated. ‡For these age groups, data from only 11 countries are included because Spain did not report data on the age of infant cases by month. §Totals do not include data separately shown for infants <1 mo, 1–5 mo, and 6–11 mo of age because those data are included in the <1 y patient age group. | |||||||||||
1Current affiliation: Hellenic Centre for Disease Control and Prevention, Athens, Greece.
2Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
3Current affiliation: Tufts University, Boston, Massachusetts, USA.
4Country experts who participated in this study are listed at the end of this article.
Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.